Literature DB >> 2416366

Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro.

L Ostlund, S Einhorn, K H Robèrt, G Juliusson, P Biberfeld.   

Abstract

The ability of interferon (IFN) to induce proliferation and differentiation in malignant B cells from 29 patients with chronic lymphocytic leukemia (CLL) and in lymphoid cells from 11 healthy donors was investigated. IFN induced transformation and plasmacytoid differentiation in B cells from 19 of 29 CLL patients. The transformed cells belonged to the malignant clone as indicated by the immunoglobulin (lg) light chain restriction. Cells exposed to IFN expressed intracellular lg to a varying degree, which was correlated to the level of plasmacytoid differentiation. IFN gave rise to proliferative responses in cells from three patients. Cytogenetic studies on lymphoid cells from one patient showed that proliferation occurred in the malignant B cells. Induction of proliferation and differentiation was observed with various alpha-IFN and gamma-IFN preparations, as well as with a completely pure beta-IFN, showing that IFN and not contaminants in the preparations were responsible for the observed effects. Maximal transformation and proliferation usually occurred after four days of incubation at an IFN concentration of 500 to 5,000 U/mL. The ability of IFN to induce differentiation in CLL cells may be of importance for the reported antitumoral effects observed in some B cell malignancies during IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416366

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass.

Authors:  E Montserrat; N Villamor; A Urbano-Ispizua; J M Ribera; M Lozano; J L Vives-Corrons; C Rozman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

2.  B-cell maturation in chronic lymphocytic leukaemia. IV. T-cell-dependent activation of leukaemic B cells by staphylococcal enterotoxin 'superantigens'.

Authors:  X Duan; C Nerl; O Janssen; D Kabelitz
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

3.  Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in hairy cell leukemia.

Authors:  R Michalevicz; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.

Authors:  L Chen; Y Mory; A Zilberstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 5.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15

Review 6.  Interferon treatment of human malignancies--a short review.

Authors:  S Einhorn; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

7.  Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients.

Authors:  W Digel; G Zahn; G Heinzel; F Porzsolt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Induction of IgM secretion by chronic B-lymphocytic leukaemia cells in serum-free medium: effects of interferon-alpha, -gamma and phorbol ester.

Authors:  T H Tötterman; M Carlsson; K Nilsson
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

9.  Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia.

Authors:  F M Uckun; A S Fauci; M Chandan-Langlie; D E Myers; J L Ambrus
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.

Authors:  A C Fluckiger; I Durand; J Banchereau
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.